Sermorelin Legal’s small print

The 2013 withdrawal finding

In March 2013, FDA published a determination about the discontinued sermorelin acetate injections: they had been withdrawn for reasons other than safety or effectiveness. The sponsor had stopped marketing them in 2008; FDA’s withdrawal of approval took effect on June 18, 2009. A few years later, the agency was answering a tightly drawn question about that exit.

The answer has a practical consequence. It preserves a route for future abbreviated new drug applications on the specified strengths. It also corrects an easy assumption: a medicine disappearing from sale can sound like a safety verdict, even when the record says otherwise.

I give that correction real weight. The same care has to apply to its boundaries. FDA was explaining a withdrawal, with particular products and strengths in view. An adult hoping for better sleep or a change in body composition is asking a further question. The old notice can only do so much work.

Is sermorelin legal?

Patient-specific compounded sermorelin can be dispensed within the applicable prescription and compounding requirements. A licensed prescriber’s order is one condition; the ingredient, pharmacy and relevant state rules also matter under Section 503A’s compounding framework. There is currently no FDA-approved finished sermorelin drug product on the U.S. market.

“Is sermorelin illegal?” therefore needs a little context. Clinical dispensing, a research-labelled sale and participation in regulated sport involve different conduct. A research label supplies no authorization for use in people. A particular person’s legal position calls for current advice from a licensed attorney or pharmacist in the relevant state.

For the narrower search question, “is sermorelin a controlled substance,” the federal answer is no: DEA’s published schedules do not enumerate sermorelin in Schedules I–V. Prescription and compounding law still apply. In sport, the 2025 WADA Prohibited List names sermorelin under S2.2.4, with prohibition both in and out of competition for athletes subject to that code.

The legal questions page deals with those distinctions individually. I’m skeptical when “legal” appears without the activity it describes.

What the old approvals covered

Sermorelin is a synthetic version of the first 29 amino acids of growth hormone-releasing hormone. It stimulates the pituitary to release the body’s own growth hormone. That made it useful both for investigating a growth hormone shortage and for treating a particular childhood condition.

The historical approval record runs from diagnostic use in 1990 to treatment of pediatric idiopathic growth hormone deficiency in 1997. In the latter condition, a child has a growth hormone shortage without an identified cause. The multicenter childhood trial reported faster linear growth during the first year. That is a substantial clinical history, with a population and an outcome attached.

Childhood growth is where sermorelin earns my respect. It gives the original approval substance, while leaving today’s adult wellness claims to stand on their own studies. The original approvals follows the diagnostic and childhood work; adult benefits and risks takes up the later ambitions.

Adult benefits

Adult research shows that the hormone system can respond. A 14-day study in healthy older men raised growth hormone and IGF-1 toward younger-adult levels. IGF-1 is a hormone produced mainly by the liver in response to growth hormone. Whether shifting those measurements produces durable improvements in everyday health requires longer and more specific evidence.

The adult anti-aging case remains limited by small studies and sparse long-term follow-up. Blackman’s editorial on secretagogues and aging judged the evidence insufficient for that purpose. The attractive mechanism deserves investigation; the clinical claims deserve a trial capable of answering them.

That distance between hormone response and adult benefit is still my central question. A past approval cannot shorten that distance. Neither can the reassurance that an old product left for commercial reasons.